Supply of ethinyloestradiol/levonorgestrel (MICROGYNON 50 ED) 50 microgram/125 microgram tablet blister pack by Bayer Australia Ltd

Overview

The Therapeutic Goods Act 1989 was enacted by the Australian Parliament to regulate the supply and quality of therapeutic goods within Australia. This legislation addresses the problem of ensuring that therapeutic goods available in the market are safe, of acceptable quality, and their benefits outweigh any risks. By providing a comprehensive regulatory framework, the Act aims to protect public health by controlling the import, supply, and advertising of therapeutic goods. In this instance, the Act is used to permit a specific exception to the usual standards for labelling of pharmaceutical products, demonstrating the flexibility of the legislation to accommodate unique situations that maintain overall public safety and health objectives. The Therapeutic Goods Act 1989 allows the Secretary of the Department of Health and Ageing to issue consents for certain deviations from standard regulatory requirements under specific conditions. In this case, the delegate of the Secretary has granted consent for Bayer Australia Ltd to supply a batch of ethinyloestradiol/levonorgestrel (MICROGYNON 50 ED) with a label that does not conform to certain standards, specifically regarding the abbreviation used for 'expiry'. This consent is conditional, applying only to a particular batch and ensuring no other changes are made, thereby maintaining the integrity and safety of the therapeutic goods supplied to the public.

Scope and Application

The Therapeutic Goods Act 1989 applies to any therapeutic goods that are manufactured, supplied, or advertised within Australia. This encompasses a wide range of products, including medicines, medical devices, blood, and tissues, and it applies to both individuals and entities involved in the production, distribution, and sale of these goods. The Act's jurisdictional reach is national, governing the therapeutic goods industry across all states and territories in Australia. The Act provides for the regulation of therapeutic goods through the Therapeutic Goods Administration (TGA), which is responsible for assessing and approving these goods for supply within Australia. The consent granted under Section 14 and 14A of the Act specifically applies to Bayer Australia Ltd, permitting them to supply a specific batch of the product ethinyloestradiol/levonorgestrel (MICROGYNON 50 ED) with certain labelling deviations, subject to the conditions outlined by the delegate of the Secretary. This consent is narrowly tailored to batch WEH57H of the specified product, ensuring that only this particular batch is allowed to deviate from the standard labelling requirements. The application of the Act can be further refined through subordinate instruments, which may introduce additional conditions or exemptions for specific products or circumstances.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 provide the legal framework for the delegate of the Secretary of the Department of Health and Ageing to give consent for the supply of therapeutic goods that do not conform to certain specifications. In this case, the delegate has consented to the supply of ethinyloestradiol/levonorgestrel (MICROGYNON 50 ED) 50 microgram/125 microgram tablet blister packs with foil labels that use the abbreviation 'ecp' instead of 'exp' for the word 'expiry' (section 14(1)). This consent is subject to specific conditions, including that it applies only to batch WEH57H of the product and that no other changes have been made to the product except for the approved formatting/design changes to the labels (section 15(1)). The obligations and requirements imposed by this consent are specific to the product in question and the particular non-conformity that has been addressed. The Company, Bayer Australia Ltd, must ensure that only the specified batch of the product with the amended foil labels is supplied. They must also ensure that no other changes have been made to the product apart from those approved by the delegate. The consent given by the delegate is a conditional approval that allows the Company to supply the product despite the non-conformity, provided that the conditions are met. Failure to comply with the conditions of the consent could have legal consequences. While specific penalties are not outlined in the notice, the Therapeutic Goods Act 1989 provides for a range of offences and penalties for breaches of the Act, including fines and imprisonment. The maximum penalties for offences under the Act can be significant, reflecting the importance of ensuring that therapeutic goods meet the required standards for safety and efficacy. The delegate may also take further action, such as recalling the product or imposing additional conditions, if it is found that the conditions of the consent have not been met. In summary, sections 14 and 14A of the Therapeutic Goods Act 1989 allow the delegate to grant consent for the supply of non-conforming therapeutic goods, subject to specific conditions. The consent given for the supply of ethinyloestradiol/levonorgestrel (MICROGYNON 50 ED) 50 microgram/125 microgram tablet blister packs with amended foil labels is conditional and must be strictly adhered to by the Company. Breaches of the conditions or of the Act more generally can result in serious legal consequences, including fines and imprisonment.